Terms: = Prostate cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Prognosis
17 results:
1. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract] [Full Text] [Related]
2. Stromal osseous metaplasia in urothelial carcinoma of the bladder: a rare case report and literature review.
Razafimahefa J; Gosset C; Mongiat-Artus P; Andriamampionona TF; Verine J
Diagn Pathol; 2019 Jul; 14(1):75. PubMed ID: 31299983
[TBL] [Abstract] [Full Text] [Related]
3. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
4. Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer.
Zhang Y; Jiang F; He H; Ye J; Mao X; Guo Q; Wu SL; Zhong W; Wu CL; Lin N
Cell Death Dis; 2018 Feb; 9(3):301. PubMed ID: 29467540
[TBL] [Abstract] [Full Text] [Related]
5. Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma.
Ye C; Tao R; Cao Q; Zhu D; Wang Y; Wang J; Lu J; Chen E; Li L
Int J Oncol; 2016 Aug; 49(2):589-602. PubMed ID: 27221337
[TBL] [Abstract] [Full Text] [Related]
6. mdm2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.
Xue L; Han X; Liu R; Wang Z; Li H; Chen Q; Zhang P; Wang Z; Chong T
Oncotarget; 2016 May; 7(22):31825-31. PubMed ID: 26025918
[TBL] [Abstract] [Full Text] [Related]
7. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Wang N; She J; Liu W; Shi J; Yang Q; Shi B; Hou P
Cell Cycle; 2015; 14(5):732-43. PubMed ID: 25590580
[TBL] [Abstract] [Full Text] [Related]
8. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
[TBL] [Abstract] [Full Text] [Related]
9. p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population.
Xu B; Mi YY; Min ZC; Cheng G; Tong N; Tao J; Li PC; Wang ML; Tang JL; Zhang ZD; Song NH; Zhang W; Wu HF; Feng NH; Hua LX
Urol Int; 2010; 85(4):401-5. PubMed ID: 20664183
[TBL] [Abstract] [Full Text] [Related]
10. mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.
Stoehr R; Hitzenbichler F; Kneitz B; Hammerschmied CG; Burger M; Tannapfel A; Hartmann A
Br J Cancer; 2008 Jul; 99(1):78-82. PubMed ID: 18577987
[TBL] [Abstract] [Full Text] [Related]
11. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients.
Woelfelschneider A; Popanda O; Lilla C; Linseisen J; Mayer C; Celebi O; Debus J; Bartsch H; Chang-Claude J; Schmezer P
Carcinogenesis; 2008 Sep; 29(9):1758-64. PubMed ID: 18332046
[TBL] [Abstract] [Full Text] [Related]
12. Novel antisense anti-mdm2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
Zhang R; Wang H; Agrawal S
Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
[TBL] [Abstract] [Full Text] [Related]
13. Combined targeting of epidermal growth factor receptor and mdm2 by gefitinib and antisense mdm2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract] [Full Text] [Related]
14. Chemosensitization and radiosensitization of human cancer by antisense anti-mdm2 oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
[TBL] [Abstract] [Full Text] [Related]
15. Alterations of p53 are common in early stage prostate cancer.
Downing SR; Russell PJ; Jackson P
Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
[TBL] [Abstract] [Full Text] [Related]
16. Experimental therapy of human prostate cancer by inhibiting mdm2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract] [Full Text] [Related]
17. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract] [Full Text] [Related]
